Melanoma Therapeutics Market Report 2025

The melanoma therapeutics market size has grown rapidly in recent years. It will grow from $4.05 billion in 2024 to $4.51 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to shift in treatment guidelines, increased awareness and early detection, regulatory approvals and clinical trials, evolution of combination therapies, advancements in surgical techniques.

The melanoma therapeutics market size is expected to see rapid growth in the next few years. It will grow to $6.84 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to emerging treatment modalities, biomarker identification, regulatory support for innovation, advancements in personalized medicine, immunotherapy enhancements. Major trends in the forecast period include evolving treatment guidelines, telemedicine in oncology, patient advocacy and awareness, biomarker research, combination therapies.

The rising incidence of melanoma is anticipated to drive the growth of the melanoma therapeutics market in the future. Melanoma is a type of skin cancer that develops from melanocytes. Melanoma therapeutics encompass the therapies and medications used to treat patients with this condition, aimed at alleviating the effects of cancer. As such, the growing incidence of melanoma directly contributes to increased sales of melanoma therapeutics. For instance, a report released by the Australian Institute of Health and Welfare in August 2024 indicates that Australia is projected to experience around 209,000 new cancer diagnoses by 2034, a notable rise from the estimated 169,000 cases expected in 2024, highlighting the influence of an expanding population and increasing cancer rates. Furthermore, cancer is expected to account for approximately 30% of all deaths in the country in 2024. Thus, the rising incidence of melanoma is propelling the growth of the melanoma therapeutics market.

The growth of the melanoma therapeutics market is anticipated to be fueled by the rising aging population. An aging population is defined as a demographic trend marked by a higher percentage or a notable rise in individuals aged 65 and older. Melanoma therapeutics are employed in this age group to address melanoma, a skin cancer that can develop at any age but becomes increasingly prevalent as people grow older. Several factors influence the administration of these treatments, including the patient's overall health, the stage of melanoma, and any existing comorbid conditions. For example, in January 2024, the Population Reference Bureau, a nonprofit organization in the US dedicated to collecting and providing statistics, estimated that the number of Americans aged 65 and older will rise from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Additionally, the proportion of the total population represented by those aged 65 and older is expected to grow from 17% to 23%. Consequently, the expansion of the aging population is contributing to the development of the melanoma therapeutics market.

Product innovation is a notable trend gaining momentum in the melanoma therapeutics market, with major companies focusing on developing new and innovative therapies to strengthen their market position. In January 2022, Immunocore, a UK-based biotechnology company, successfully developed KIMMTRAK (tebentafusp-tebn), receiving FDA approval for the treatment of metastatic uveal melanoma. KIMMTRAK is a groundbreaking bispecific protein with anti-CD3 immune-effector activity linked to a soluble T cell receptor, demonstrating an overall survival of nearly 22 months in a successful phase 3 clinical trial. This represents the first compound created using Immunocore's ImmTAC technology platform, redirecting and activating T lymphocytes to identify and eliminate tumor cells.

Major companies in the melanoma therapeutics market are introducing innovative products such as Opdualag to enhance their market profitability. Opdualag, a medication for the treatment of melanoma that has spread or cannot be surgically removed, was approved by the FDA in March 2022. Developed by Bristol Myers Squibb, Opdualag is a breakthrough combination therapy targeting both PD-1 and LAG-3, improving efficacy and tolerability compared to current immunotherapies. This provides a novel treatment option for advanced melanoma patients, enhancing the effectiveness of existing immunotherapies without significantly increasing side effects.

In April 2022, EMZ Partners, a Germany-based investment firm, acquired a majority stake in FotoFinder Systems GmbH for an undisclosed amount. This strategic partnership is expected to enable FotoFinder Systems GmbH to expand its product offerings and reach new markets. FotoFinder Systems GmbH, based in Germany, provides skin visualization equipment used in melanoma therapeutics.

Major companies operating in the melanoma therapeutics market include AstraZeneca plc, Eli Lilly and Company, Merck & Co. Inc., Novartis AG, Sanofi S.A., AB Science S.A, Amgen Inc., Daiichi Sankyo Company Limited, F. Hoffman-La Roche Ltd., Pfizer Inc., Bayer AG, AbbVie Inc., Johnson & Johnson Private Limited, The Bristol-Myers Squibb Company, Nektar Therapeutics, Immutep Ltd., Partner Therapeutics lnc., Idera Pharmaceuticals Inc., Oncolys BioPharma Inc., Iovance Biotherapeutics lnc., AIM ImmunoTech Inc., Infinity Pharmaceuticals lnc., Spring Bank Pharmaceuticals lnc., Incyte Corporation, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Eisai Co.Ltd., Seattle Genetics Inc., Regeneron Pharmaceuticals Inc., Bio-Rad Laboratories Inc., Myriad Genetics Inc.

North America was the largest region in the melanoma therapeutics market in 2024. The regions covered in the melanoma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the melanoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Melanoma therapeutics refer to treatment procedures employed for addressing melanoma, a form of skin cancer that originates in the melanocytes. These therapies operate by targeting abnormal cells, either by directly eliminating them or by impeding their growth and multiplication.

The primary categories of melanoma therapeutic drugs include monoclonal antibodies, small-molecule inhibitors, and others. Monoclonal antibodies are synthetic therapeutic proteins designed to bind to specific targets, such as antigens present in cancer cells, and are produced in laboratory settings. Various treatment modalities are encompassed, such as surgery, radiation therapy, immunotherapy, targeted therapy, and chemotherapy, and these therapies are administered through various routes, including oral and injectable methods. Melanoma is categorized into different types, including superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral lentiginous melanoma, amelanotic melanoma, and others. Diagnosis involves techniques such as dermatoscopy, sentinel lymph node biopsy, blood tests, x-rays, ultrasound, and CT scans.

The melanoma therapeutics market research report is one of a series of new reports that provides melanoma therapeutics market statistics, including melanoma therapeutics industry global market size, regional shares, competitors with a melanoma therapeutics market share, detailed melanoma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the melanoma therapeutics industry. This melanoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The melanoma therapeutics market includes revenues earned by entities by providing stereotactic radiosurgery, stereotactic ablative radiation therapy, intralesional therapy, and palliative therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.